Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1486 to 1500 of 1688 results for carers

  1. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued [GID-TAG507]

  2. Urinary tract infection (recurrent): antimicrobial prescribing (NG112)

    This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

  3. Cellulitis and erysipelas: antimicrobial prescribing (NG141)

    This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.

  4. Alzheimer's disease (early) - gantenerumab [ID6142]

    In development [GID-TA11269] Expected publication date: TBC

  5. Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]

    In development [GID-TA11272] Expected publication date: TBC

  6. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued [GID-TA11151]

  7. Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]

    In development [GID-TA11010] Expected publication date: TBC

  8. Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]

    In development [GID-TA11411] Expected publication date: TBC

  9. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued [GID-TA11261]

  10. Rolofylline for the treatment of acute heart failure [ID96]

    Discontinued [GID-TA11258]

  11. Capecitabine for the treatment of advanced pancreatic cancer [ID127]

    Discontinued [GID-TA11239]

  12. Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]

    Discontinued [GID-TA11240]

  13. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued [GID-TA11241]

  14. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701

    In development [GID-TA11157] Expected publication date: TBC

  15. ALXN1840 for treating Wilson disease TS ID 9950

    In development [GID-TA11449] Expected publication date: TBC